Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04166487 · ClinicalTrials.gov registry record · Phase 2
Plasma-Adapted First-Line Pembro In NSCLC
A Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV, sponsored by Julia K. Rotow, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT04166487: Active Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV, sponsored by Julia K. Rotow, MD.
NCT04166487 is a Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV that is active but no longer recruiting, run by Julia K. Rotow, MD. The registered enrollment target is 40 participants, below the 381-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04166487, a Phase 2 study of Metastatic Non Small Cell Lung Cancer and NSCLC Stage IV, is active but no longer recruiting, sponsored by Julia K. Rotow, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in combination with chemotherapy. The names of the study drugs involved in this study are: * Pembrolizumab * Platinum doublet chemotherapy, which may include the following: * Carboplatin and pemetrexed * Carboplatin and paclitaxel The name of the blood test: \- InVision (Inivata, Ltd.)
Primary Outcome
Kaplan-Meier method
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG PEMETREXED
- DRUG CARBOPLATIN
- DRUG PACLITAXEL
- DIAGNOSTIC_TEST InVision
Study Locations (5)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Boston Medical Center - Boston
- Dana-Farber at Steward St. Elizabeth's Medical Center - Brighton
- Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital - South Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
What the registry record for NCT04166487 still lists
NCT04166487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 381-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04166487 lists 5 locations in 1 state (Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04166487 about?
NCT04166487 is a clinical study titled "Plasma-Adapted First-Line Pembro In NSCLC". This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue trea...
What is the current status of trial NCT04166487?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-01-13. Estimated completion is 2026-12-01.
What conditions does trial NCT04166487 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, NSCLC Stage IV.
What interventions are being tested in trial NCT04166487?
The interventions under investigation include: Pembrolizumab (DRUG), PEMETREXED (DRUG), CARBOPLATIN (DRUG), PACLITAXEL (DRUG), InVision (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04166487?
This trial is sponsored by Julia K. Rotow, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04166487 being conducted?
This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04166487's enrollment target sits among peer trials
40 24th of 31 higher than 6 of 31 other Metastatic Non Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RECRUITING · Phase 2
-
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RECRUITING · Phase 2
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI